It's crunch time this week for Spanish firm Zeltia SA. Since late last month, the Madrid-based company has been engaged in an unusually vocal lobbying campaign on behalf of its cancer drug Yondelis, which the London-based European Medicines Evaluation Agency is currently evaluating. (BioWorld International) Read More
